Zentalis Pharmaceuticals, Inc.
ZNTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001725160
In the last 90 days, Zentalis Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 114 institutions reported holding it in 13F filings for Q2 2026, worth $228.9M in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Zentalis Pharmaceuticals, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 110
- +4 vs. Q4 2022
- Shares held
- 67.0M
- +2.68M (+4.2%) vs. Q4 2022
- Total value
- $1.15B
- −$143.0M (−11.0%) vs. Q4 2022
- New holders
- 13
- 40 more added
- Sold out
- 9
- 35 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ZNTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 114 | $228.9M |
| Q1 2026 | 102 | $101.7M |
| Q4 2025 | 86 | $54.9M |
| Q3 2025 | 99 | $79.7M |
| Q2 2025 | 117 | $64.5M |
| Q1 2025 | 132 | $92.9M |
| Q4 2024 | 142 | $195.2M |
| Q3 2024 | 136 | $261.2M |
| Q2 2024 | 145 | $314.3M |
| Q1 2024 | 142 | $1.34B |
| Q4 2023 | 120 | $1.23B |
| Q3 2023 | 137 | $1.61B |
| Q2 2023 | 134 | $2.32B |
| Q1 2023 | 110 | $1.15B |
| Q4 2022 | 106 | $1.30B |
| Q3 2022 | 121 | $1.27B |
| Q2 2022 | 122 | $1.64B |
| Q1 2022 | 128 | $2.05B |
| Q4 2021 | 139 | $3.61B |
| Q3 2021 | 116 | $2.75B |
| Q2 2021 | 120 | $2.13B |
| Q1 2021 | 95 | $1.58B |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Zentalis Pharmaceuticals, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Price T Rowe Associates Inc | 2,200,169 | $37.8M | 0.01% | +23,469+1.1% | Added |
| State Street Corp | 2,832,023 | $48.7M | 0.00% | −252,114−8.2% | Reduced |
| Avidity Partners Management LP | 2,929,300 | $50.4M | 1.67% | −2,220,700−43.1% | Reduced |
| Capital International Investors | 3,127,758 | $53.8M | 0.01% | +79,576+2.6% | Added |
| Eventide Asset Management, LLC | 3,227,000 | $55.5M | 1.02% | +1,070,485+49.6% | Added |
| Wellington Management Group LLP | 3,360,329 | $57.8M | 0.01% | −258,164−7.1% | Reduced |
| BlackRock Inc. | 3,417,467 | $58.8M | 0.00% | −54,712−1.6% | Reduced |
| Vanguard Group Inc | 4,240,615 | $72.9M | 0.00% | +80,466+1.9% | Added |
| FMR LLC | 8,912,751 | $153.3M | 0.01% | +1,003,575+12.7% | Added |
| Matrix Capital Management Company, LP | 9,199,973 | $158.2M | 2.15% | 00.0% | Unchanged |
| Opaleye Management Inc. | 0 | $0 | 0.00% | −167,500−100.0% | Sold out |
| Candriam Luxembourg S.C.A. | 0 | $0 | 0.00% | −127,973−100.0% | Sold out |
| Gyon Technologies Capital Management, LP | 0 | $0 | 0.00% | −42,905−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −20,054−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −13,600−100.0% | Sold out |
| ProShare Advisors LLC | 0 | $0 | 0.00% | −10,759−100.0% | Sold out |
| Rockefeller Capital Management L.P. | 0 | $0 | 0.00% | −288−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −9−100.0% | Sold out |